92 related articles for article (PubMed ID: 22415782)
1. Subtractive genomics approach to identify putative drug targets and identification of drug-like molecules for beta subunit of DNA polymerase III in Streptococcus species.
Georrge JJ; Umrania VV
Appl Biochem Biotechnol; 2012 Jul; 167(5):1377-95. PubMed ID: 22415782
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Identification of druggable targets for Acinetobacter baumannii via subtractive genomics and plausible inhibitors for MurA and MurB.
Kaur N; Khokhar M; Jain V; Bharatam PV; Sandhir R; Tewari R
Appl Biochem Biotechnol; 2013 Sep; 171(2):417-36. PubMed ID: 23846799
[TBL] [Abstract][Full Text] [Related]
4. In silico study and validation of phosphotransacetylase (PTA) as a putative drug target for Staphylococcus aureus by homology-based modelling and virtual screening.
Morya VK; Dewaker V; Kim EK
Appl Biochem Biotechnol; 2012 Dec; 168(7):1792-805. PubMed ID: 23054816
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Miguet L; Zervosen A; Gerards T; Pasha FA; Luxen A; Distèche-Nguyen M; Thomas A
J Med Chem; 2009 Oct; 52(19):5926-36. PubMed ID: 19746934
[TBL] [Abstract][Full Text] [Related]
6. Structure-based approaches to antibiotic drug discovery.
Nicola G; Abagyan R
Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
[TBL] [Abstract][Full Text] [Related]
7. An insight into the exploration of druggable genome of Streptococcus gordonii for the identification of novel therapeutic candidates.
Azam SS; Shamim A
Genomics; 2014 Sep; 104(3):203-14. PubMed ID: 25068724
[TBL] [Abstract][Full Text] [Related]
8. An Approach for Identification of Novel Drug Targets in Streptococcus pyogenes SF370 Through Pathway Analysis.
Singh S; Singh DB; Singh A; Gautam B; Ram G; Dwivedi S; Ramteke PW
Interdiscip Sci; 2016 Dec; 8(4):388-394. PubMed ID: 26750924
[TBL] [Abstract][Full Text] [Related]
9. Mycoplasma genitalium: a comparative genomics study of metabolic pathways for the identification of drug and vaccine targets.
Butt AM; Tahir S; Nasrullah I; Idrees M; Lu J; Tong Y
Infect Genet Evol; 2012 Jan; 12(1):53-62. PubMed ID: 22057004
[TBL] [Abstract][Full Text] [Related]
10. [Problems with identification of beta-hemolytic streptococcus resistant to bacitracin isolated from patients with pharyngitis].
Olender A; Łetowska I; Karyński M; Kiernicka-Ciekot K; Pels K
Med Dosw Mikrobiol; 2012; 64(1):1-10. PubMed ID: 22808724
[TBL] [Abstract][Full Text] [Related]
11. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era.
Dougherty TJ; Miller PF
IDrugs; 2006 Jun; 9(6):420-2. PubMed ID: 16752312
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
13. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
[TBL] [Abstract][Full Text] [Related]
14. Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III.
Guiles J; Sun X; Critchley IA; Ochsner U; Tregay M; Stone K; Bertino J; Green L; Sabin R; Dean F; Dallmann HG; McHenry CS; Janjic N
Bioorg Med Chem Lett; 2009 Feb; 19(3):800-2. PubMed ID: 19109016
[TBL] [Abstract][Full Text] [Related]
15. mef(A), mef(E) and a new mef allele in macrolide-resistant Streptococcus spp. isolates from Norway.
Sangvik M; Littauer P; Simonsen GS; Sundsfjord A; Dahl KH
J Antimicrob Chemother; 2005 Nov; 56(5):841-6. PubMed ID: 16172106
[TBL] [Abstract][Full Text] [Related]
16. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.
Miller JR; Herberg JT; Tomilo M; McCroskey MC; Feilmeier BJ
Anal Biochem; 2007 Jun; 365(1):132-43. PubMed ID: 17395144
[TBL] [Abstract][Full Text] [Related]
17. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems.
Kellenberger E; Foata N; Rognan D
J Chem Inf Model; 2008 May; 48(5):1014-25. PubMed ID: 18412328
[TBL] [Abstract][Full Text] [Related]
18. [Sensitivity of Streptococcus pneumoniae to antimicrobial drugs].
Mihajlović-Ukropina M; Milutinović M
Med Pregl; 1998; 51(3-4):169-73. PubMed ID: 9611963
[TBL] [Abstract][Full Text] [Related]
19. Postgenomic strategies in antibacterial drug discovery.
Brötz-Oesterhelt H; Sass P
Future Microbiol; 2010 Oct; 5(10):1553-79. PubMed ID: 21073314
[TBL] [Abstract][Full Text] [Related]
20. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
Ioerger TR; Sacchettini JC
Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
